

Special Issue

Therapeutic Antibodies: New Trends in Discovery, Developability and Characterization

Message from the Guest Editors

The development of therapeutic antibodies has continued its success story in recent years. Every year, around a dozen antibodies are approved by regulatory authorities in the US and EU for the treatment of cancer or other diseases, such as autoimmune diseases. The development pipelines of research-based pharmaceutical companies are well filled. However, there are new trends in the techniques used to discover suitable antibody candidates and test their developability and modes of action. First and foremost is the integration of artificial intelligence and machine learning tools to generate antibodies with tailored properties and predict their developability. Lastly, new antibody formats and engineered variants will provide new or improved functionalities.

This Special Issue on therapeutic antibody discovery, development, and characterization will present new technology developments and applications in the field. Researchers will present their latest results, and review articles will cover new developments.

Guest Editors

Dr. Anne Zeck

NMI, Natural and Medical Sciences Institute at the University of Tuebingen, 72770 Reutlingen, Germany

Dr. David J Vance

Division of Infectious Diseases, Wadsworth Center, New York State Department of Health, Albany, NY 12208, USA

Deadline for manuscript submissions

20 October 2026



Antibodies

an Open Access Journal
by MDPI

Impact Factor 2.7
CiteScore 4.5
Indexed in PubMed



mdpi.com/si/219096

Antibodies
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
antibodies@mdpi.com

[mdpi.com/journal/
antibodies](https://mdpi.com/journal/antibodies)





Antibodies

an Open Access Journal
by MDPI

Impact Factor 2.7
CiteScore 4.5
Indexed in PubMed



[mdpi.com/journal/
antibodies](https://mdpi.com/journal/antibodies)



About the Journal

Message from the Editor-in-Chief

Antibodies is a relatively new journal with a major focus on quick dissemination of knowledge related to antibodies, especially how to quickly translate basic research results to therapeutic applications. Because it covers all areas related to antibodies unexpected connections between different areas could be made, leading to major discoveries and opening new fields of research and development. This is enhanced by the large readership of the many antibody-related areas of research. A specific priority area is human monoclonal antibodies for therapy of diseases and aging.

Editor-in-Chief

Prof. Dr. Arne Skerra

Institute of Biological Chemistry, Technical University Munich, Emil-Erlenmeyer-Forum 5, 85350 Freising-Weihenstephan, Germany

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, ESCI (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

CiteScore - Q2 (Drug Discovery)